



3705 DT02 Rec'd PTO 04 MAR 2005 PCT #7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/517,214
Filed: 11/23/2004
1st Inventor: Tsuyoshi MAEKAWA
For: 1,2-Azole Derivatives with Hypoglycemic and
Hypolipidemic Activity
Atty. Dkt. No. 3065 USOP

Art Unit: tba
Examiner: tba
Allowed:
Batch:
Paper No.:

Substitute Information Disclosure Statement

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request reconsideration of the references listed on the attached substitute Forms PTO/SB/08A and PTO/SB/08B to correct References A18 and A29. A legible copy of each listed reference has been previously provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted

Dated: 3/3/05

(847) 383-3372
(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA



Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
is a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 5 |
|-------|---|----|---|

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/517,214 |
| Filing Date | 11/23/2004 |
| First Named Inventor | Tsuyoshi MAEKAWA |
| Art Unit | tba |
| Examiner Name | tba |
| Attorney Docket Number | 3065 USOP |

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|----------|---|------------------|---|---|---|
| Examiner Initials* | Cite No. | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | 1 |
| | | Country Code* Number* Kind Code* (If Known) | MM-DD-YYYY | | | |
| | A6 | EP 1216980 A1 | 06/26/2002 | Eisai Co., Ltd. | | |
| | A7 | CA 2,100,546 | 01/25/1994 | B. Mueller, et al. | | |
| | A8 | EP 0558062 A2 | 09/01/1993 | Ono Pharmaceutical | | |
| | A9 | EP 0442448 A2 | 08/21/1991 | Bristol-Myers Squibb | | |
| | A10 | WO 03/015771 A1 | 02/27/2003 | Lion Bioscience AG | | |
| | A11 | WO 00/64876 | 11/02/2000 | Aventis Pharmaceuticals | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

EXAMINER: Include if/ reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Initial copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter ISO 3166-1 (MPEP Standard ST-3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/517,214 |
| Filing Date | 11/23/2004 |
| First Named Inventor | Tsuyoshi MAEKAWA |
| Art Unit | tba |
| Examiner Name | tba |
| Attorney Docket Number | 3065 USOP |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | A27 | BARREIRO, E.J., et al., "Synthesis of Pyrazole Derivatives as Potential Bioisosteres of Thromboxane-Synthetase Inhibitors", Journal of Heterocyclic Chemistry, (1992), pp. 407-411, Vol. 29. | |
| | A28 | Database Crossfire Beilstein 'Online', Database Accession No. 4424469, XP002253755, abstract & Chem. Heterocycl. Compd. (Engl. Transl.), Vol. 20, No. 1, (1984), p. 114. | |
| | A29 | Database Crossfire Beilstein 'Online', Database Accession No. 649155, XP002253756, abstract & J. Chem. Soc. Perkin Trans. 1, (1974), pp. 1871-1875. | |
| | A30 | Database Crossfire Beilstein 'Online', Database Accession No. 7211617, XP002253757, abstract & Heterocycles, (1955), pp. 515-520, Vol. 40, No. 2 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.